New research reveals that patients who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end traditional lifestyle plans.
Research printed in a major medical journal shows that while obese people can lose about a fifth of their body weight while on the medication, the mass comes back at an estimated rate of nearly a kilo each month once they quit.
"Users purchasing these drugs need to be informed of the potential of quick weight regain when the medication ends," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain means a return to starting weight within about 18 months.
Weighing Treatments
The analysis, which looked at dozens of studies involving over 9,000 of participants, compared the outcomes of the injectable medications with other pills.
Scientists point out that people who lose weight through dieting usually see a more gradual weight regain—around 0.1 kg a month—after stopping.
Understanding the Quick Rebound
Doctors suggest the mode of action of the jabs is key to understanding the amplified regain.
GLP-1 drugs copy a natural hormone called GLP-1, which helps regulate hunger.
"Sustained high doses of the hormone concentrations far above than normal might result in the body to generate a reduced amount of its own natural GLP-1, and could reduce sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this medication means appetite is unsuppressed, making binge eating much more probable."
A Chronic Condition?
Medical guidelines recommend the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals say that, considering the significant potential of relapse, the therapy should be considered ongoing.
This view is reinforced by pharmaceutical companies, who state that the results "underscore the chronic nature of excess weight," comparing it to managing diseases like hypertension.
Patient Testimonies
Individuals who have stopped the medication explain a powerful return of cravings.
"It felt as if a switch activating and you're instantly extremely hungry," said a patient.
This difficulty is exacerbated if users have not established lasting dietary or behavioural modifications during therapy.
Significant Interest
Survey data show that millions of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Adoption is higher among females than men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, researchers caution that while these medications are potent agents for shedding pounds, they are not a permanent cure and lasting health benefits likely depends on integrated behavioural management.
